Loading company…
Syndax Pharmaceuticals develops therapies for cancer and other serious diseases.
Founded in 2005 and based in New York, Syndax Pharmaceuticals focuses on oncology drug development. Its therapies include revumenib and axatilimab, which were approved in the US in 2024, and are also being studied for other indications. The company has completed 14 deals, with its most recent listed deal on March 2, 2016.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in